A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-20. Anything still debated is marked as such rather than presented as settled.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
== H == HAADF – High angle annular dark-field imaging HAS – Helium atom scattering HPLC – High performance liquid chromatography HREELS – High resolution electron energy loss spectroscopy HREM – High-resolution electron microscopy HRTEM – High-resolution transmission electron microscopy HI-ERDA – Heavy-ion elastic recoil detection analysis HE-PIXE – High-energy proton induced X-ray emission
The trial followed participants for 29 days and included 1,033 participants with moderate or severe COVID-19; 515 participants received baricitinib plus remdesivir, and 518 participants received placebo plus remdesivir. Recovery was defined as either being discharged from the hospital or being hospitalized but not requiring supplemental oxygen and no longer requiring ongoing medical care. The median time to recovery from COVID-19 was seven days for baricitinib plus remdesivir and eight days for placebo plus remdesivir. The odds of a patient's condition progressing to death or being ventilated at day 29 was 31% lower in the baricitinib plus remdesivir group versus the placebo plus remdesivir group. The odds of clinical improvement at day 15 was 30% higher in the baricitinib plus remdesivir group versus the placebo plus remdesivir group. For all of these endpoints, the effects were statistically significant. The EUA was issued to Eli Lilly and Company. In November 2020, the World Health Organization (WHO) updated its guideline on therapeutics for COVID-19 to include a conditional recommendation against the use of remdesivir, triggered by results from the WHO Solidarity trial. In November 2020, the FDA issued an emergency use authorization (EUA) for the combination of baricitinib with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized people aged two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
== Research and academic contributions == Eke's research focuses on optimizing the safe and effective use of medications in pregnancy and lactation. His work spans pharmacokinetics, pharmacodynamics, pharmacoepidemiology, pharmacogenomics, and pharmacometrics. He has led clinical and translational research on drug safety, dosing, and interactions in pregnant women, particularly in relation to preterm birth, HIV, hepatitis C, tuberculosis, sickle cell disease, hypertensive disorders of pregnancy, and substance use disorders. His studies integrate approaches such as longitudinal cohort designs, intensive and sparse pharmacokinetic sampling, population-based modeling, physiologically based pharmacokinetic modelling, and real-world data analysis. He has pioneered the use of high-dimensional omics such as proteomics and metabolomics in investigating the pathophysiology of complex pregnancy-related conditions. This work contributes to the development of personalized pharmacotherapy strategies and regulatory guidance for medication use during pregnancy. Eke has received multiple research grants from the NIH, including a Women's Reproductive Health Research (WRHR) Career Development award, a K23 Career Development award, and a National Institutes of Health Director's Pioneer Award (DP1), which supports innovative and high-impact research.
Sources: en.wikipedia.org
From April to May 2024, Rio Grande do Sul was hit by massive flooding, which also severely hit Porto Alegre. This was partly seen as, in addition to the sheer amount of precipitation, insufficient pumping of water, as trash and rubble had blocked many manholes in the city. Melo, during the flooding, affirmed that the city government knew that there was a possibility of strong rains and was not taken by surprise. He denied, however, that the city government had delayed its response and put the responsibility on the new round of floodings for the high volume, as well as the population, blaming them for the trash strewn throughout the city. During the floods, the Guaíba hit its highest ever historical level, leaving various parts of the city submerged and many people stranded. Due to the severity of the situation, the municipality set up 21 centers to receive thousands of people who were forced to leave their homes. The flooding was also marked by conflicts between Melo and the federal government, during which he criticized what he saw was the lack of support from them, despite having also delayed a formal emergency request for days. During this period, federal deputy Fernanda Melchionna and city councilman Roberto Robaina, both from PSOL, sued Melo. They both requested that the State Attorney's Office to start an investigation against Melo due to the fact that the municipal government had not sent the federal government the data of families in Porto Alegre hit by the floods.
=== Pharmacodynamics === Methenamine has non-specific antiseptic and antibacterial properties in acidic environments via hydrolysis into formaldehyde. Formaldehyde is an aldehyde and is highly reactive and thereby bactericidal. It acts by binding to and denaturing bacterial proteins and nucleic acids. Methenamine is almost completely inactive as an antibacterial in alkaline environments, in which it is not degraded into formaldehyde. The drug's spectrum of antibacterial activity includes all urinary tract pathogens. It is specifically effective against common UTI-causing bacteria including Staphylococcus saprophyticus, Escherichia coli, Enterococcus faecalis, and Enterococcus faecium. However, Klebsiella aerogenes (Enterobacter aerogenes) has been said to generally be resistant to methenamine, although the mechanism and rationale supporting this resistance have not been described. In addition, certain urea-splitting bacteria, such as Proteus and Pseudomonas species, can make the urine more alkaline, thereby potentially inhibiting the antibacterial effects of methenamine. Providencia and Morganella species are also urea-splitting and might likewise be resistant to methenamine, although this topic requires more research. Methenamine is provided medically as the hippuric acid or mandelic acid salt, and the acid salt component plays a key role in helping to make the urine more acidic such that the activity of methenamine is optimized. Ascorbic acid (vitamin C), sodium acid phosphate, or ammonium chloride can also be supplemented to further acidify the urine.
== Contraindications == Ampicillin/sulbactam is contraindicated in individuals who have a history of a penicillin allergy. Symptoms of allergic reactions may range from rash to potentially life-threatening conditions, such as anaphylaxis. Patients who have asthma, eczema, hives, or hay fever are more likely to develop undesirable reactions to any of the penicillins.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.